EDI Graphic with text.png

T R A N S F O R M I N G    D I S C O V E R I E S    I N T O    M E D I C I N E S

The Empire Discovery Institute (EDI) is designed to help overcome key challenges typically faced by life science researchers in academia – lack of external funding to continue research efforts and lack of pharmaceutical industry expertise to advance these programs to fruition. 

Dr. Martin Graham, EDI’s Chief Executive Officer, has convened an expert panel of Scientific Advisory Board members. These members are all experienced pharmaceutical industry veterans with expertise in drug discovery & design, medicinal chemistry, drug formulation, pharmacology, toxicology, FDA regulatory strategy, clinical development, business development, biotechnology company entrepreneurship and drug product commercialization. Our aim is to identify medically important pathways and targets related to human disease that will serve as the basis for the discovery and development of novel, highly differentiated new therapeutics. 

M E D I C I N E S    D I S C O V E R Y    A W A R D    P R O G R A M

  • $100,000 up to $7.5M in program support over five years (reviewed annually)

  • Access to EDI’s Scientific Advisory Board, strategic partners & consultant network

  • Drug discovery and development expertise

  • Project management & planning

  • Business and commercialization advice

  • Assistance in company incorporation & management

  • Clinical development advice

  • Regulatory strategy & IND preparation assistance

  • IP review and filing support

  • Assistance identifying and securing additional finance (based on program needs)

EDI is interested in programs that provide novel insights into the pathways and molecular determinants of human disease.  It prefers programs that have a clear mechanism of action or possess a well-defined genetic basis for the underlying condition and projects with a strong biomarker component are highly desirable. EDI accepts applications across a wide range of therapeutic areas providing a strong scientific, medical and commercial rationale can be made.  Programs in the fields of cancer, neurological diseases/CNS conditions and platform technologies with therapeutic potential across multiple diseases are of particular interest.  Investigators working in the rare and orphan diseases are also encouraged to apply.

In close collaboration with its Scientific Advisory Board, EDI will help researchers design and conduct preclinical testing of promising compounds discovered in their laboratories. Investigators will also receive expert assistance in de novo drug design, medicinal chemistry, pre-clinical testing, drug formulation, pharmacology and safety testing to advance candidate drugs through the various phase of pre-clinical testing to the first-in-human (IND stage) clinical trials. 

To apply to the EDI Medicines Discovery Award Program, please visit our website.

A B O U T     U S 

MARTIN GRAHAM, PhD

Chief Executive Officer

Dr Martin Graham joined the Empire Discovery Institute in April 2019. He is a successful drug developer and serial entrepreneur with over 30 years of experience in the development of small molecule drugs and biologics including Oxaliplatin (colorectal cancer), Stelara (psoriasis), Remicade (rheumatoid arthritis & Crohn’s disease and Elitek (rasburicase) for tumor lysis syndrome.  He brings a wealth of pharmaceutical industry experience with Sterling-Winthrop, Sanofi, Centocor, Johnson & Johnson, and venture backed biotechnology companies including TetraLogic Pharmaceuticals. Prior to joining EDI, Martin was the CEO, President and Founder of PKPD Biosciences (a pharmacokinetic modeling & simulation company) which he merged with his second company KinderPharm, a pediatric drug development

KinderPharm, a pediatric drug development company before being acquired by Synteract.  Martin earned his PhD. from the University of London Drug Development Section, Institute of Cancer Research, Royal Marsden Hospital, London;  his B.Sc. from the University of Leeds in Pharmacology and Microbiology; and is an Honorary Professor of Pharmacokinetic Modeling & Simulation at the School of Life Sciences, Institute of Pharmaceutical Innovation University of Bradford, England.  Martin also serves as a Scientific Advisor to the Harrington Discovery Institute & BioMotiv LLC, an early stage drug discovery accelerator that is part of the Harrington Project.

Get In Touch